中山康方生物医药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma 2021-10-15 12:44
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA 2021-09-24 14:09
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA 2021-09-24 09:18
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China 2021-08-06 09:39
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia 2021-07-13 09:06
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor 2021-06-30 16:00
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States 2021-05-24 18:17
ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer 2020-08-13 20:07
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee 2020-06-24 12:55
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting 2019-11-11 17:35
Akeso, Inc. Completes Series-D Private Financing for US$150 Million 2019-11-09 00:43
1 2 3 4